To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period

NAEnrolling by invitationINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions
Diabetes MellitusContinuous Glucose Monitoring System
Interventions
DEVICE

iCan o3 CGM Continuous Glucose Monitoring System

"A continuous Glucose Monitoring System (CGM System) is a real-time, continuous glucose monitoring device indicated for the management of diabetes for adult persons (age 18 and older). It is intended to replace finger prick blood glucose testing for diabetes treatment decisions. The CGM System also shows trends and tracks patterns, and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the CGM System results should be based on the glucose trends and several sequential readings over time.~The CGM System can be used in conjunction with smart devices with corresponding applications (apps) where the user manually controls actions for therapy decisions. During this study, Self-Monitoring Blood Glucose (SMBG) assessed by an iCan o3 CGM System blinded to the patient for 15 days as the baseline and unblinded observation period using an iCan o3 CGM System for 45 days occurs."

Trial Locations (1)

Unknown

UZA ANTWERP UZA Dienst Endocrinologie, Antwerp

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Archer Research

INDUSTRY

lead

Sinocare

INDUSTRY

NCT06904846 - To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period | Biotech Hunter | Biotech Hunter